Amerikanische Gesellschaft für Hirudotherapie

Characterization of active peptides derived from three leeches and comparison of their anti-thrombotic mechanisms using the tail vein thrombosis model in mice and metabonomics

Research article published in Frontiers in pharmacology (2024)

Zuletzt aktualisiert: 18. Juni 2026Geprüft von: ASH Editorial Board
Forschungsartikel – EvidenzreviewArtikelreferenz
Evidence: Research reportArzneimittelentwicklungDong Y et al. · Frontiers in pharmacology, 2024

Abstract

Background and aims: The increasing incidence of cardiovascular diseases has created an urgent need for safe and effective anti-thrombotic agents. Leech, as a traditional Chinese medicine, has the effect of promoting blood circulation and removing blood stasis, but its real material basis and mechanism of action for the treatment of diseases such as blood stasis and thrombosis have not been reported. Methods: In this study, Whitmania Pigra Whitman (WPW), Hirudo nipponica Whitman (HNW) and Whitmania acranutata Whitman (WAW) were hydrolyzed by biomimetic enzymatic hydrolysis to obtain the active peptides of WPW (APP), the active peptides of HNW (APH) and the active peptides of WAW (APA), respectively. Then their structures were characterized by sykam amino acid analyzer, fourier transform infrared spectrometer (FT-IR), circular dichroism (CD) spectrometer and LC-MS. Next, the anti-thrombotic activities of APP, APH and APA were determined by carrageenan-induced tail vein thrombosis model in mice, and the anti-thrombotic mechanisms of high-dose APP group (HAPP), high-dose APH group (HAPH) and high-dose APA group (HAPA) were explored based on UHPLC-Q-Exactive Orbitrap mass spectrometry. Results: The results showed that the amino acid composition of APP, APH and APA was consistent, and the proportion of each amino acid was few different. The results of FT-IR and CD showed that there were no significant differences in the proportion of secondary structures (such as β-sheet and random coil) and infrared absorption peaks between APP, APH and APA. Mass spectrometry data showed that there were 43 common peptides in APP, APH and APA, indicating that the three have common material basis. APP, APH and APA could significantly inhibit platelet aggregation, reduce black-tail length, whole blood viscosity (WBV), plasma viscosity (PV), and Fibrinogen (FIB), and prolong coagulation time, including activated partial thrombin time (APTT), prothrombin time (PT) and thrombin time (TT). In addition, 24 metabolites were identified as potential biomarkers associated with thrombosis development. Among these, 19, 23, and 20 metabolites were significantly normalized after administration of HAPP, HAPH, and HAPA in the mice, respectively. Furthermore, the intervention mechanism of HAPP, HAPH and HAPA on tail vein thrombosis mainly involved in linoleic acid metabolism, primary bile acid biosynthesis and ether lipid metabolism. Conclusion: Our findings suggest that APP, APH and APA can exert their anti-blood stasis and anti-thrombotic activities by interfering with disordered metabolic pathways in vivo, and there is no significant difference in their efficacies.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article

Zusammenfassung

Characterization of active peptides derived from three leeches and comparison of their anti-thrombotic mechanisms using the tail vein thrombosis model in mice and metabonomics.

Warum dies für die Hirudotherapie relevant ist

Diese Studie charakterisierte aktive Peptide, die aus drei Blutegeln – Whitmania Pigra Whitman (WPW), Hirudo nipponica Whitman (HNW) und Whitmania acranutata Whitman (WAW) – durch biomimetische enzymatische Hydrolyse gewonnen wurden, und verglich ihre antithrombotischen Aktivitäten an einem Carrageen-induzierten Schwanzvenen-Thrombosemodell bei Mäusen. Die Autoren berichten, dass die drei Peptidpräparate 43 gemeinsame Peptide teilten, die Thrombozytenaggregation signifikant hemmten, die Schwarzschwanzlänge, die Vollblutviskosität, die Plasmaviskosität und das Fibrinogen reduzierten sowie die Gerinnungszeiten verlängerten, ohne signifikanten Wirksamkeitsunterschied zwischen ihnen. Metabolomische Analysen zeigten eine Intervention in Stoffwechselwege einschließlich Linolsäuremetabolismus, primärer Gallensäure-Biosynthese und Etherlipid-Metabolismus. Die Arbeit ist direkt relevant für aus Blutegeln stammende bioaktive Moleküle und ihre antithrombotischen Wirkungen, ist jedoch präklinisch und verwendet enzymatische Hydrolysate in einem Tiermodell statt Lebend-Hirudotherapie.

Zitation

Characterization of active peptides derived from three leeches and comparison of their anti-thrombotic mechanisms using the tail vein thrombosis model in mice and metabonomics

Dong Y et al. · Frontiers in pharmacology, 2024

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: 18. Juni 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Freigabe für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.